Urolithin D is a competitive, reversible EphA receptor antagonist derived from ellagitannin gut metabolism. It suppresses EphA2 phosphorylation in prostate cancer cells and reduces triglyceride accumulation in adipocyte and hepatocyte cultures, making it a valuable research tool for studying cancer signaling and metabolic disorders such as NAFLD.